Oxford Biomedica plc (LON:OXB - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 336.94 ($4.37) and traded as high as GBX 405.50 ($5.26). Oxford Biomedica shares last traded at GBX 405 ($5.25), with a volume of 150,001 shares traded.
Analyst Ratings Changes
Separately, Deutsche Bank Aktiengesellschaft increased their price target on shares of Oxford Biomedica from GBX 250 ($3.24) to GBX 380 ($4.93) and gave the stock a "hold" rating in a report on Tuesday, September 24th.
Check Out Our Latest Report on OXB
Oxford Biomedica Trading Up 1.8 %
The stock has a market cap of £426.71 million, a PE ratio of -281.25 and a beta of 1.09. The company has a debt-to-equity ratio of 154.88, a quick ratio of 1.67 and a current ratio of 2.35. The company has a 50 day moving average of GBX 370.86 and a two-hundred day moving average of GBX 337.93.
About Oxford Biomedica
(
Get Free Report)
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
Read More
Before you consider Oxford Biomedica, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oxford Biomedica wasn't on the list.
While Oxford Biomedica currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
